We use first- and third-party cookies to provide our services and collect statistical data. By continuing to browse you accept these cookies.
More information
Accept
Home
About us
NEURAXPHARM
HISTORY HIGHLIGHTS
EXECUTIVE COMMITTEE
COMMITED TO SOCIETY
CNS SPECIALIST
CNS FOCUS
THERAPEUTIC AREAS
CNS R&D STRATEGY
Products
OUR PORTFOLIO
CNS VALUE ADDED MEDICINES
CNS STANDARD GENERICS
CNS CONSUMER HEALTHCARE
Other Services
FDFs – LESVI
CMO / BFS
GENERIC DOSSIERS
APIs – INKE
DEVELOPMENT & MANUFACTURING
REGULATORY SUPPORT
JOIN US
CONTACT US
NEWSROOM
LINKEDIN
Neuraxpharm group
See Neuraxpharm’s sites
Austria
Czechia
France
Germany
Hungary
Italy
Poland
Portugal
Slovakia
Spain
United Kingdom
Manufacturing plants
FDFs | LESVI
APIs | INKE
Newsroom
Neuraxpharm launches first probiotic product PS128™
28 MAY
Read more
Interview with Dr Dierks, Neuraxpharm's CEO, published on Puls Medycyny
24 APR
Read more
Thank you for visiting our stand at the EPA Congress 2019
22 APR
Read more
Neuraxpharm attends 27th European Congress of Psychiatry
05 APR
Read more
Neuraxpharm starts operations in Poland
03 APR
Neuraxpharm Group announces expansion in Eastern Europe with the launch of Neuraxpharm Polska
Read more
1
2
3
4
5
